Journal of the advanced practitioner in oncology · 2024
Obinutuzumab Infusion-Related Reactions: Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zacholski Erin Hickey, Rugh Sarah, Marshall Jenna, Nadpara Pramit, Moore Donald
Аннотация
INTRODUCTION: Despite standard prevention strategies, obinutuzumab carries a significant risk of infusion-related reactions (IRRs) for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Reported rates of IRRs vary in phase III clinical trials evaluating obinutuzumab-containing regimens. Although obinutuzumab has a higher rate of severe (grade 3 and higher) IRRs than rituximab, clinical risk factors predicting IRR have not been identified, and therefore strata informing patient-specific risk of IRR have not been applied in practice.
METHODS: This multicenter, retrospective evaluation of patients with CLL/SLL estimated the incidence of obinutuzumab-related IRRs and evaluated risk factors for the development of IRR in a real-world population.
RESULTS: 68 patients with untreated or previously treated CLL/SLL were included in the analysis, with the majority being older adult (median age = 70) males (61.8%) with Rai stage III and IV CLL. All-grade IRRs occurred in 25% of patients, and severe IRRs occurred in 1.5% of patients. Of the variables evaluated, absolute lymphocyte count was a significant predictor (p ≤ .05) of the odds of experiencing an IRR in patients receiving obinutuzumab.
CONCLUSION: Obinutuzumab IRR rates in a real-world population were comparable to most phase III clinical trial results succeeding implementation of split dosing and standard premedication. Absolute lymphocyte count is a statistically significant predictor for increased odds of experiencing an IRR. Future research evaluating risk-adapted obinutuzumab administration strategies is needed to recommend a specific approach.
METHODS: This multicenter, retrospective evaluation of patients with CLL/SLL estimated the incidence of obinutuzumab-related IRRs and evaluated risk factors for the development of IRR in a real-world population.
RESULTS: 68 patients with untreated or previously treated CLL/SLL were included in the analysis, with the majority being older adult (median age = 70) males (61.8%) with Rai stage III and IV CLL. All-grade IRRs occurred in 25% of patients, and severe IRRs occurred in 1.5% of patients. Of the variables evaluated, absolute lymphocyte count was a significant predictor (p ≤ .05) of the odds of experiencing an IRR in patients receiving obinutuzumab.
CONCLUSION: Obinutuzumab IRR rates in a real-world population were comparable to most phase III clinical trial results succeeding implementation of split dosing and standard premedication. Absolute lymphocyte count is a statistically significant predictor for increased odds of experiencing an IRR. Future research evaluating risk-adapted obinutuzumab administration strategies is needed to recommend a specific approach.